AGN 201904 [AGN-201904Z] versus esomeprazole in the prevention of aspirin-induced stomach or upper intestinal damage in healthy volunteers

Trial Profile

AGN 201904 [AGN-201904Z] versus esomeprazole in the prevention of aspirin-induced stomach or upper intestinal damage in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs AGN 201904Z; Esomeprazole
  • Indications NSAID-induced gastrointestinal damage
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 01 Jun 2011 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
    • 22 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top